Kymera adds to the clinical picture for protein degraders
The company digs into the biological effects of its IRAK4 degrader
The latest clinical data from Kymera adds to the growing body of evidence that targeted degraders are effective at depleting proteins in humans, and gives a fuller picture of downstream biological effects.
At the 4th Annual Targeted Protein Degradation Summit on Wednesday, Kymera Therapeutics Inc. (NASDAQ:KYMR) presented data from its Phase I trial of KT-474 in healthy volunteers, the first randomized, double-blind, placebo-controlled trial for a protein degrader. The trial will recruit up to 20 patients with atopic dermatitis (AD) or hidradenitis suppurativa (HS) in 1Q22, with a data readout expected mid-year. ...